On August 21, 2025 Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jechobio"), a global, clinical stage biopharmaceutical company advancing medicines focusing in oncology, reported that the National Medical Products Administration (NMPA) has delivered a Notice of Approval for Drug Clinical Trial for JLM019 injection in the treatment of advanced malignant tumors (Press release, Jecho Laboratories, AUG 21, 2025, View Source [SID1234655425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The NMPA’s clearance of our Investigational New Drug application is an important regulatory milestone for Jechobio. JLM019 represents a potential first-in-class next generation IO therapy. We look forward to the expected dosing of the first patient with JLM019 in the next few months," said Dr. Xiaodong Xiao, CEO of Jechobio.

Jechobio anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in Q4 2025.

About JLM019

JLM019 is an innovative CD80/PD-1 dual-targeted Fc fusion protein that simultaneously blocks immunosuppression and activates immunostimulation. JLM019 injection exhibits broad-spectrum anti-tumor properties and has demonstrated significant anti-tumor activity in multiple solid tumor models, offering hope for the treatment of patients with advanced cancer.